Daratumumab + European Standard Yields Clinical Benefit in Transplant Eligible, Newly Diagnosed Myeloma

New data from the CASSIOPEIA trial evaluated the  use of daratumumab in addition to bortezomib/thalidomide/dexamethasone after ASCT in multiple myeloma.

Source: CancerNetwork - June 3, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news